The Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2018

Amendment of the Misuse of Drugs Regulations (Northern Ireland) 2002

2.—(1) The Misuse of Drugs Regulations (Northern Ireland) 2002(1) are amended as follows.

(2) In paragraph 1(a) of Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27)—

(a) Before “Bufotenine” insert—

• “Adinazolam (1-(8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine)

• N-Benzyl-ethylphenidate

• Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)”

(b) after “Cathinone” insert—

• “4’-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)”;

(c) after “Concentrate of poppy-straw” insert—

• “Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)

• 3,4-Dichloroethylphenidate

• 3,4-Dichloromethylphenidate (3,4-DCMP)

• Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1.3-dihydro-2H-1,4-benzodiazepin-2-one)”;

(d) after “3-Dimethylheptyl-11-hydroxyhexahydrocannabinol” insert—

• “Ethylnaphthidate

• Ethylphenidate”;

(e) after “Eticyclidine” insert—

• “Etizolam”;

(f) after “Etryptamine” insert—

• “Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)

• 4-Fluoroethylphenidate

• 4-Fluorometylphenidate

• Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)”;

(g) after “9-Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10, 10a- tetrahydrobenzo[c]chromen-1-ol” insert—

• “3-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Isopropylphenidate (IPP or IPPD)”;

(h) after “Lysergide and other N-alkyl derivatives of lysergamide” insert—

• “Meclonazepam (5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)”;

(i) after “Methcathinone” insert—

• “4-Methylmethylphenidate

• Methylmorphenate

• Methylnaphthidate (HDMP-28)N-methyl-1-(thiophen-2-yl)propan-2-amine (methiopropamine or MPA)

• Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)

• Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Nitrazolam (1-Methyl-8-nitro-6-phenyl-4H-[1,2,4] triazolo[4,3-a][1,4]benzodiazepine)

• Propylphenidate”;

(j) after “Psilocin” insert—

• “Pyrazolam (8-Bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)”;

(k) after “3,4-dichloro-N-[[1-(dimethylamino)cyclohexy]methyl]benzamide (AH-7921)” insert—

• “3,4-dichloro-N-[2-dimethylamino)cyclohexyl]-N-methylbenzamide (U-47,700)”;

(3) After paragraph 1(c) of Schedule 1, insert —

“(ca) any compound (not being clonitazene, etonitazene, acemetacin, atorvastatin, bazedoxifene, indometacin, losartan, olmesartan, proglumetacin, telmisartan, viminol, zafirlukast or a compound for the time being specified in sub-paragraph (c) above) structurally related to 1-pentyl-3-(1-naphthoyl)indole (JWH-018), in that the four substructures, that is to say the indole ring, the pentyl substituent, the methanone linking group and the naphthyl ring, are linked together in a similar manner, whether or not any of the sub-structures have been modified, and whether or not substituted in any of the linked sub-structures with one or more univalent substituents and, where any of the sub-structures have been modified, the modifications of the sub-structures are limited to any of the following, that is to say—

(i) replacement of the indole ring with indane, indene, indazole, pyrrole, pyrazole, imidazole, benzimidazole, pyrrolo[2,3-b]pyridine, pyrrolo[3,2-c]pyridine orpyrazolo[3,4-b]pyridine;

(ii) replacement of the pentyl substituent with alkyl, alkenyl, benzyl,cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, 2-(4-morpholinyl)ethyl or (tetrahydropyran-4-yl)methyl;

(iii) replacement of the methanone linking group with an ethanone, carboxamide, carboxylate, methylene bridge or methine group;

(iv) replacement of the 1-naphthyl ring with 2-naphthyl, phenyl, benzyl, adamantyl, cycloalkyl, cycloalkylmethyl, cycloalkylethyl, bicyclo[2.2.1]heptanyl, 1,2,3,4-tetrahydronaphthyl, quinolinyl, isoquinolinyl, 1-amino-1-oxopropan-2-yl, 1-hydroxy-1-oxopropan-2-yl, piperidinyl, morpholinyl, pyrrolidinyl, tetrahydropyranyl or piperazinyl.”

(4) In paragraph 1 of Part 2 of Schedule 4 (which specifies Controlled Drugs Excepted from the Prohibition on Possession; Excluded from the Application of Offences Arising from the Prohibition on Importation and Exportation when Carried Out in Person for Administration to That Person; and Subject to the Requirements of Regulations 22, 23, 26 and 27), after “Desoxymethyltestosterone” insert—

• “Dienedione (estra-4, 9-diene-3, 17-dione)”.

(1)

S.R. 2002 No. 1